TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02928211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire II
Description: A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aftobetin-HCl
Description: The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
Study: NCT01692093

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KM110329
Description: KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02720211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gray tinted spectacle lenses
Description: A neutral gray optical tint designed to block all wavelengths in the visible spectrum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thin-Film spectacle lenses
Description: A thin film optical notch filter designed to block 480-nm light in the visible spectrum
Study: NCT00359047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Documentation
Description: Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
Study: NCT01536171

Intervention type: OTHER
Intervention: running with normal running shoes and barefoot
Description: shod condition: normal running shoes barefoot condition: running with no shoewear
Study: NCT02849405

Intervention type: DEVICE
Group type: OTHER
Intervention: MHRC: Metabolic Hyperspectral Retinal Camera
Description: Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.

Intervention type: DEVICE
Group type: OTHER
Intervention: MHRC: Metabolic Hyperspectral Retinal Camera
Description: Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
Study: NCT01748305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity exercise
Description: Moderate-to-vigorous intensity exercise three times per day for three weeks
Study: NCT03928392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCUBA with Occupational Therapy (OT)
Description: Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Contained Underwater Breathing Apparatus (SCUBA) without OT
Description: Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
Study: NCT00288223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telithromycin
Description: one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
Study: NCT05168098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: board game comparison
Description: The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
Study: NCT00892515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study: NCT05168098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory stimulation intervention
Description: The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
Study: NCT04191408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP increase
Description: PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
Study: NCT01621789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dye of lutein, zeaxanthin, trypan blue
Description: dye composed of lutein, zeaxanthin, trypan blue
Study: NCT02900898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic exercise and Mediterranean diet
Description: DE, MD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Description: DE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: MD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control
Study: NCT04271046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-C-VTF
Description: 1. One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~2. Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~3. secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm.
Study: NCT04451837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Ozempic s.c. once weekly for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Forxiga 10 mg p.o. once daily for 6 months
Study: NCT02421536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrogent Smartphone Application
Study: NCT02780895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Stem Cells
Description: MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery.
Study: NCT01486381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT00885326

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).

Intervention type: DRUG
Group type: OTHER
Intervention: zoledronic acid
Description: Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
Study: NCT02378298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iv Methylprednisolone
Description: Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peroral methylprednisolone and Methotrexate
Description: Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
Study: NCT02854618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study: NCT00801411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT03445117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
Study: NCT01700283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise education and walking program
Description: 12-week moderate intensity walking program
Study: NCT03842436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital pill
Description: Digital pills over encapsulating Truvada

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada prescribed with digital pills for PrEP
Study: NCT04417400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medicines use review
Description: The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
Study: NCT00002740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT00892515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiologic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study of high risk factors
Study: NCT05128045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEW-R
Description: Eight session class on nutrition, physical activity, diet, and weight management
Study: NCT02109445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Study: NCT02041052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy as an adjunct to traditional whipple procedure.
Description: Subtotal gastrectomy as an adjunct to traditional whipple procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional whipple procedure
Description: All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
Study: NCT01001806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine 0.45%
Description: One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromfenac 0.09%
Description: One day pre operative 1 drop BID then 3 doses pre op day of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac 0.1%
Description: One drop BID, 1 day pre operative and then 3 doses the day of surgery
Study: NCT01065714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogel vehicle
Description: Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucerin Lotion
Description: Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
Study: NCT05155930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal Family Systems (IFS)
Description: Weekly individual psychotherapy
Study: NCT02972450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine
Description: The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine
Description: The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab
Description: The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
Study: NCT00839917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)
Description: Single administration of 0.5 mL subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R™ II and Varivax™
Description: Single administration of 0.5 mL subcutaneous injection
Study: NCT02701946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Robert Jones bandage
Description: Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non compressive dressing
Description: Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.